Roth Capital Remains Positive on Stemline (STML); Management Updates on SL-401, SL-701
Tweet Send to a Friend
Roth Capital affirms Stemline Therapeutics (Nasdaq: STML) at Buy with a price target of $62 following a recent management update.Analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
